Insider Buying: Indaptus Therapeutics, Inc. (NASDAQ:INDP) CEO Buys $18,240.00 in Stock
Insider Buying: Indaptus Therapeutics, Inc. (NASDAQ:INDP) CEO Buys $18,240.00 in Stock
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) CEO Jeffrey A. Meckler bought 9,600 shares of the company's stock in a transaction that occurred on Monday, November 21st. The stock was purchased at an average price of $1.90 per share, for a total transaction of $18,240.00. Following the transaction, the chief executive officer now owns 75,374 shares of the company's stock, valued at $143,210.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Indaptus治療公司(納斯達克代碼:INDP-GET評級)首席執行官傑弗裏·A·梅克勒在11月21日星期一的一筆交易中購買了9,600股該公司股票。股票是以每股1.90美元的平均價格購買的,總交易額為18,240.00美元。交易完成後,這位首席執行官現在持有該公司75,374股股票,價值143,210.60美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的,該文件可在此超鏈接.
Indaptus Therapeutics Stock Performance
Indaptus Treateutics股票表現
Indaptus Therapeutics stock opened at $1.80 on Friday. Indaptus Therapeutics, Inc. has a 12 month low of $1.64 and a 12 month high of $7.10. The stock's 50 day simple moving average is $2.00 and its two-hundred day simple moving average is $2.43.
Indaptus治療公司的股票週五開盤報1.80美元。Indaptus Treateutics,Inc.的12個月低點為1.64美元,12個月高點為7.10美元。該股的50日簡單移動均線切入位為2.00美元,200日簡單移動均線切入位為2.43美元。
Institutional Investors Weigh In On Indaptus Therapeutics
機構投資者看好Indaptus治療公司
Several hedge funds have recently bought and sold shares of the stock. Northern Trust Corp purchased a new stake in Indaptus Therapeutics in the 1st quarter worth approximately $41,000. State Street Corp purchased a new stake in Indaptus Therapeutics in the 1st quarter worth approximately $78,000. Renaissance Technologies LLC purchased a new stake in Indaptus Therapeutics in the 2nd quarter worth approximately $51,000. Vanguard Group Inc. boosted its position in Indaptus Therapeutics by 18.7% in the 1st quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock worth $969,000 after purchasing an additional 38,216 shares in the last quarter. Finally, Strategy Asset Managers LLC purchased a new stake in Indaptus Therapeutics in the 3rd quarter worth approximately $120,000. Hedge funds and other institutional investors own 19.25% of the company's stock.
幾家對衝基金最近買賣了該股的股票。北方信託公司在第一季度購買了Indaptus治療公司的新股份,價值約41,000美元。道富集團在第一季度購買了Indaptus Treeutics的新股份,價值約7.8萬美元。復興技術公司在第二季度購買了Indaptus治療公司的新股份,價值約51,000美元。先鋒集團在第一季度將其在Indaptus治療公司的地位提高了18.7%。先鋒集團目前持有242,235股該公司股票,價值96.9萬美元,上個季度又購買了38,216股。最後,Strategy Asset Manager LLC在第三季度購買了Indaptus Treeutics的新股份,價值約12萬美元。對衝基金和其他機構投資者持有該公司19.25%的股份。
Indaptus Therapeutics Company Profile
Indaptus治療公司簡介
Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.
Indaptus治療公司是一家臨牀前生物技術公司,開發各種抗癌和抗病毒免疫療法產品。它的主要臨牀腫瘤學候選藥物Decoy20對淋巴瘤、肝細胞腫瘤、結直腸腫瘤和胰腺腫瘤以及乙肝病毒和人類免疫缺陷病毒感染的單一藥物活性和/或聯合治療的持久反應,正在進行I期臨牀試驗。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- 免費獲取StockNews.com關於Indaptus治療的研究報告(INDP)
- 微軟股票:是時候備份卡車了嗎?
- 機構對ADI的支持仍然很高
- Salesforce裁員,儘管面臨挑戰,但收入強勁
- 60/40的投資組合組合還在《時尚》雜誌上流行嗎?
- 三隻CBD股票將主宰一個萌芽行業
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Indaptus治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Indaptus治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。